|
KMID : 0939920230550010344
|
|
대한암학회지
2023 Volume.55 No. 1 p.344 ~ p.349
|
|
|
Osimertinib Combined with Systemic Chemotherapy for EGFR Mutant, T790M-Negative, Non?Small Cell Lung Cancer Patients Who Develop Leptomeningeal Metastases with Extracranial Progression to Prior EGFR TKI
|
|
Kim Hye-Ryeon
Jo Hyun-Ji
Kim Hong-Sik
Hong Joo-Hyun
Park Se-Hoon
Jung Hyun-Ae
Lee Se-Hoon
Ahn Jin-Seok
Ahn Myung-Ju
|
|
|
Abstract
|
|
|
|
Leptomeningeal metastasis (LM) is a rare but fatal clinical condition with a short survival time. The incidence of LM from epidermal growth factor receptor mutant (EGFRm) non?small cell lung cancer (NSCLC) has increased due to the limited efficacy of first- or second-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) in the central nervous system (CNS). Osimertinib is a third-generation, irreversible, CNS penetrant, oral EGFR TKI that demonstrates promising efficacy in CNS metastases regardless of T790M. Herein, we report four cases of T790M-negative EGFRm NSCLC patients treated with osimertinib combined with systemic chemotherapy, who progressed on prior EGFR TKI and developed LM with extracranial lesions. The combination treatment was well tolerated, and the mean overall survival from LM diagnosis was 14.7 months (95% confidence interval, 10.4 to 19.0). These results suggest that osimertinib combined with systemic chemotherapy would be a reasonable treatment option for T790M-negative EGFRm NSCLC patients who develop LM with extracranial progression to prior EGFR TKI. A further prospective study is warranted.
|
|
|
KEYWORD
|
|
|
Leptomeningeal metastasis, EGFR mutant NSCLC, Osimertinib, Systemic chemotherapy
|
|
|
FullTexts / Linksout information
|
|
|
|
|
Listed journal information
|
|
    
|